Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 130

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 130
---
 senior management, and
their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity,
and permit us to advance the expenses of defending any act, suit or proceeding to members of our board of directors and senior management.

In addition, under general
principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such
employee in the proper execution of his or her duties under the employment agreement with the Company.

We have entered into indemnification
agreements with each of the members of our board of directors and senior management in the form to be filed as an exhibit to this registration
statement upon the completion of this offering. We have also obtained directors’ and officers’ liability insurance to cover
certain actions undertaken by our board of directors and senior management.

Insofar as indemnification
for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers and
controlling persons of the Company, the Company has been advised that, in the opinion of the Securities and Exchange Commission, such
indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.

<div align='center'>II-1</div>

Item 9. Exhibits

| Exhibit 
 Number  |     | Description of Document                                                                                                                                                                                                                        |
| 1.1*    |     | Form of Underwriting Agreement                                                                                                                                                                                                                 |
| 2.1     |     | Agreement and Plan of Merger, dated November 4, 2024, by and between NLS Pharmaceutics, NLS Pharmaceutics (Israel Ltd.), and Kadimastem Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-39957) filed November 5, 2024).                  |
| 2.2     |     | Amendment to the Agreement and Plan of Merger, dated January 30, 2025, by and between NLS Pharmaceutics, NLS Pharmaceutics (Israel Ltd.), and Kadimastem Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-39957) filed January 31, 2025). |
| 3.1     |     | Amended and Restated Articles of Association of NLS Pharmaceutics Ltd. (filed as Exhibit